Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Despite the large amount of research and reporting on potential biomarkers in cancer, very few markers have been brought to use in the clinic. Disorganization plays a large part in this low yield. The Early Detection Research Network (EDRN) of the National Cancer Institute has been initiated to foster collaboration among independent institutions/ laboratories to facilitate, standardize, and centralize discovery and validation of candidate biomarkers. EDRN comprises four components: biomarker reference laboratories; biomarker developmental laboratories; clinical epidemiology and validation centers; and a data management and coordinating center. Biomarker validation proceeds through five phases-the preclinical exploratory, clinical assay and validation, retrospective longitudinal, prospective screening, and cancer control phases. A number of candidate markers in colon cancer, esophageal adenocarcinoma, and hepatocellular carcinoma (HCC) currently are moving through the developmental process. Ongoing EDRN collaborations assessing the potential utility of des-gamma carboxyprothrombin (DCP) in discriminating early HCC in patients with cirrhosis and the ability of DNA methylation analysis to predict progression from Barrett's esophagus to esophageal cancer are summarized. EDRN welcomes collaboration in biomarker validation and assembly of sample reference libraries.
 ...
PMID:Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach. 1936 Jan 50

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), such as gefitinib or erlotinib, is mainly metabolized in liver. To date, the safety data on administrating EGFR-TKI to patients with liver dysfunction is quite limited. Here, we administered gefitinib to two adenocarcinoma patients with liver cirrhosis, and one patient with EGFR gene mutation in exon 21 achieved long stable disease (SD) without any toxicity. Pharmacokinetic data of alternate days administration in these patients were similar to those of daily administration in patients with normal liver function. Although further studies are needed, a reduced dose of gefitinib might be feasible for patients with liver dysfunction.
 ...
PMID:Gefitinib for non-small cell lung cancer patients with liver cirrhosis. 1975 73

The main causes of death in patients with liver transplants are derived from the graft itself. Given the increased survival in this group of patients, the rate of de novo neoplasms in other locations is increasing. We present the case of a 60-year-old man who underwent orthotopic liver transplantation 10 years earlier for terminal cirrhosis caused by hepatitis B. Imaging studies showed dilation of the intra- and extra-hepatic bile ducts with no evidence of lithiasis, anastomotic stenosis, or other biliary complications that are common in patients with liver transplants. The definitive diagnosis was reached by endoscopic retrograde cholangiopancreatography. Adenocarcinoma of the ampulla of Vater should be considered among the causes of biliary obstruction in patients with orthotopic liver transplants.
 ...
PMID:[Biliary obstruction due to adenocarcinoma of the ampulla of Vater ten years after orthotopic liver transplantation]. 1983 32

A 65-year-old woman was admitted to our hospital with progressive confusion and hypersomnia. During admission she became comatose which was found to be caused by hepatic encephalopathy. Fifteen years earlier she had undergone a Whipple's pancreaticoduodenectomy for an adenocarcinoma of the pancreatic head. She had developed secondary endo- and exocrine pancreas insufficiency and a fatty liver. Non-alcoholic fatty liver disease (NAFLD) is a little-known late complication of a pancreaticoduodenectomy, possibly caused by postoperative exocrine pancreas insufficiency. NAFLD may lead to non-alcoholic steatohepatitis (NASH) which can ultimately result in liver cirrhosis. There have been no previous reports in the literature of hepatic encephalopathy presenting as liver failure secondary to NASH following pancreaticoduodenectomy.
 ...
PMID:[Hepatic encephalopathy following a Whipple operation]. 1985 76

Liver transplantation may occasionally be indicated in patients with unique clinical scenarios. Little is known regarding the outcomes of patients who have had a pancreatic resection prior to, in combination with, or after liver transplantation. A retrospective review of all patients undergoing liver transplantation from March 1998 to March 2008 identified 17 patients who also underwent pancreatic resection. An additional literature review was performed. Five underwent pancreatic resection prior to liver transplantation (1.7, 3.6, 3.8, 6.8, and 8.1 years), another 9 underwent pancreatic resection together with liver transplantation, and 3 underwent pancreatic resection after liver transplantation (2.2, 2.6, and 3.8 years). Indications for pancreatic resection included cholangiocarcinoma (n = 6), neuroendocrine tumor (n = 5), pancreatic cancer (n = 2), gastrointestinal stromal tumor (n = 1), periampullary adenocarcinoma (n = 1), duodenal adenomas (n = 1), and benign pancreatic mass (n = 1). Indications for liver transplantation were metastatic neuroendocrine tumor disease (n = 5), primary sclerosing cholangitis (n = 5), hepatitis C virus (n = 2), metastatic gastrointestinal stromal tumor (n = 1), Klatskin tumor (n = 1), alcohol cirrhosis (n = 1), alpha-1 antitrypsin deficiency (n = 1), and chemotherapy-induced cirrhosis (n = 1). One patient died intraoperatively, 7 patients died of tumor recurrence, 2 patients died from transplant complications, and 7 patients are still alive. Pancreatic resection-related complications included 4 pancreatic fistulas. A literature review confirmed liver transplantation/pancreatic resection-related complications. In conclusion, liver transplantation and pancreatic resection remain uncommon, and a good outcome can be achieved. Recurrence of malignant disease is the main factor limiting survival, and specific morbidity may be related to pancreatic resection and liver transplantation.
 ...
PMID:Liver transplantation and pancreatic resection: a single-center experience and a review of the literature. 1993 25

A 54-year-old man underwent Hartmann's operation for rectal cancer in October 2003. Diagnostic images showed a single liver tumor in segment 7 of the liver in March 2004. He had a non-B, non-C cirrhosis. Liver damage was defined as B and ICG retention rate after 15 minutes was 54%. Platelet count was 7x10(4)-11x10(4)/mm3 and PT activity was 59%. The S7 tumor size was 6.5 cm in diameter, and we planned a partial resection of the liver. Intraoperative histological diagnosis of needle biopsy showed a metastatic adenocarcinoma from rectal cancer. Because of tuberculous peritonitis, it was difficult to control oozing from dissected plane. Therefore, we changed the method of operation from a partial resection to microwave coagulation therapy (MCT). To avoid a deteriorating liver function, we did not perform any adjuvant chemotherapy. He is alive without recurrence for five years after surgery. Nevertheless metastatic liver tumor is more than 5 cm and in cirrhotic liver, if the tumor located superficial parenchyma, MCT may have a possibility to be a curative treatment.
 ...
PMID:[A five-year survived case of more than 5 cm colorectal liver metastases treated with intraoperative microwave coagulation therapy]. 2003 67

It has been clearly established that Helicobacter pylori (H. pylori) infection plays a pivotal role in the pathogenesis of chronic gastritis, peptic ulcer, gastric adenocarcinoma, and gastric lymphoma MALT (mucosa-associated lymphoid tissue) in the general population, but data regarding the prevalence and the role of H. pylori infection in liver cirrhosis are conflicting. Most serological studies estimated a high prevalence of H. pylori infection in patients with liver cirrhosis; however, when other methods (urea breath test, histology, culture, rapid urease test) were used, the overall H. pylori prevalence was similar to that in controls. Although the prevalence of both gastric ulcer (GU) and duodenal ulcer (DU) is higher in cirrhotic patients than in general population, the relationship between H. pylori infection and peptic ulcer in cirrhosis remains controversial. Our data regarding peptic ulcer prevalence in cirrhotic patients are in agreement with previous studies that suggest an increased prevalence of both GU and DU. The incidence of bleeding peptic ulcer is high in cirrhotic patients and carries an increased risk of complications or death in these patients and therefore eradication of H. pylori infection might be as effective in preventing ulcer relapse and bleeding as it is in noncirrhotic ulcer patients. Hepatic encephalopathy is a frecquent complication of liver cirrhosis, and it is widely accepted that ammonia plays a major role in its pathogenesis. The ammonia production by H. pylori urease does not increase blood ammonia levels during cirrhosis, and eradication of H. pylori infection does not affect hepatic encephalopathy status.
 ...
PMID:[Prevalence and role of Helicobacter pylori infection in some gastroduodenal and hepatic complications in cirrhotic patients]. 2020 58

Hepar lobatum carcinomatosum is an unusual cause of chronic liver failure, usually maskerading as cirrhosis. The pathogenesis of this syndrome is unclear. We report a case of liver failure revealing an occult lobular carcinoma of the breast, which offers the opportunity to gain further insight into the mechanisms of this rare cause of chronic liver disease. A 57-year-old woman, without history of malignancy, presented with hepatomegaly, ascites and altered liver tests (serum transaminase activity >5 N and hyperbilirubinemia). The transjugular liver biopsy performed at diagnosis showed an extensive fibrosis, containing scattered tumor cells, typical of metastatic lobular carcinoma of the breast. Four months later, after discovery of a rectal adenocarcinoma, a laparoscopy was performed; peritoneal carcinomatosis was discovered. A surgical biopsy of the liver was taken during the procedure: it showed histological features suggestive of chronic Budd-Chiari syndrome, with venocentric fibrosis and reversed lobulation. Intraluminal invasion of small hepatic veins and sinusoidal obstruction by neoplastic cells were observed. A small focus of lobular carcinoma was eventually discovered in the left mammary gland. The present case report expands the spectrum of clinical presentations associated with hepar lobatum carcinomatosum and points out to the importance of vascular injury in the pathogenesis of this rare cause of chronic liver disease.
 ...
PMID:Hepar lobatum carcinomatosum revealing an occult metastatic lobular carcinoma of the breast. 2107 93

Herein we present a 73-year-old man with primary carcinosarcoma of the liver, a rare malignant tumor of the liver. The case was followed up due to HBV-related liver cirrhosis. Regular check-up by ultrasound demonstrated a hyperechoic tumor in the left lobe of the liver, and he was referred and admitted to our hospital. Dynamic CT studies revealed a mostly hypoenhancing hepatic mass with a peripheral ring enhancement. Surgical resection was performed, and the resected tumor was macroscopically a simple nodular type, 3 cm in diameter, with a dense fibrous capsule. Microscopically, undifferentiated cells were dominant in the tumor, while moderately differentiated hepatocellular carcinoma (HCC) were also observed. A transitional zone was noted between the undifferentiated tumor and HCC. Tumor tissue with adenocarcinoma, osteosarcoma and chondrosarcoma were also detected. Immunohistochemical studies demonstrated that tumor cells were HepPar 1 positive in hepatocellular carcinoma, and CK19 and partly CK7 positive in adenocarcinoma. Moreover, CD56, chromogranin A and c-kit were occasionally positive in undifferentiated tumor cells. The diagnosis of carcinosarcoma was made based on the concomitant presence of HCC and sarcomatous components, yet it is noteworthy that various types of tumor cells were observed.
 ...
PMID:Carcinosarcoma of the liver. 2113 95

Even after extensive preoperative assessment, staging laparoscopy may allow avoidance of non-therapeutic laparotomy in patients with radiographically occult metastatic or locally unresectable disease. Staging laparoscopy is associated with decreased postoperative pain, a shorter hospital stay and a higher likelihood of receiving systemic therapy compared to laparotomy but its yield has decreased with improvements in imaging techniques. Current uses of staging laparoscopy include the following: (1) In the staging of pancreatic adenocarcinoma, laparoscopic staging allows for the identification of sub-radiographic metastatic disease in locally advanced cancer in approximately 30% of patients and, in radiographically resectable cancer, may identify metastatic disease in 10%-15% of cases; (2) In colorectal liver metastases, selective use of laparoscopic staging in patients with a clinical risk score of over 2 identifies unresectable disease in approximately 20% of patients; (3) In hepatocellular carcinoma, laparoscopic staging could be selectively used in high-risk patients such as those with clinically apparent liver cirrhosis and in patients with major vascular invasion or bilobar tumors; and (4) In biliary tract malignancy, staging laparoscopy may be used in all patients with potentially resectable primary gallbladder cancer and in selected patients with T2/T3 hilar cholangiocarcinoma. Because of the decreasing yield of SL secondary to improvements in imaging techniques, staging laparoscopy should be used selectively for patients with pancreatic and hepatobiliary malignancy to avoid unnecessary non-therapeutic laparotomy and to improve resource utilization. Each individual surgeon should apply his or her threshold as to whether staging laparoscopy is indicated according to the quality of preoperative imaging studies and the availability of resources at their own institution.
 ...
PMID:Role of staging laparoscopy in peri-pancreatic and hepatobiliary malignancy. 2116 Aug 97


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>